The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Recent data (PMID 26980577) cast some doubt about the existence of leflunomide-induced pneumonitis
Publications
Leflunomide-induced interstitial lung disease (a systematic review).
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG. 2013;30(3):167-76
Clinical expression of leflunomide-induced pneumonitis.
Rheumatology (Oxford, England). 2009;48(9):1065-8
Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis.
Arthritis and rheumatism. 2006;54(5):1435-9
Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports.
Internal medicine journal. 2006;36(3):162-9
Interstitial lung disease associated with leflunomide.
Internal medicine (Tokyo, Japan). 2004;43(12):1103-4